Loading
Obesity / Berobenatide · Phase 3 Trial
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 3 randomized controlled trial of berobenatide for obesity in Japanese adults, planned but not yet recruiting. No results are reported in this registry entry; the study is in the planning phase with a primary endpoint of percent change in body weight at 72 weeks.
Phase 3, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Obesity; age from 18 Years. Intervention: Treatment Arm 1; Treatment Arm 2; Treatment Arm 3. Compared with: Placebo — Placebo Comparator. n = 180. 12 sites: Japan.
This is a registered Phase 3 randomized controlled trial of berobenatide for obesity in Japanese adults, planned but not yet recruiting. No results are reported in this registry entry; the study is in the planning phase with a primary endpoint of percent change in body weight at 72 weeks.
This is a registry record only; no efficacy or safety results are reported.
The source did not state who this applies to in practice.
This is a registered Phase 3 trial that has not yet recruited or reported results; the registry entry describes only the planned design and primary outcome measure, with no efficacy or safety data available.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07794761). This is a study registration, not published results. Lead sponsor: Pfizer. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 180 participants (ESTIMATED). Conditions: Obesity. Interventions: DRUG: Berobenatide; OTHER: Placebo. Primary outcome measures: Percent change from baseline in body weight , Baseline, Week 72. Brief summary: The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition where a person has too much body fat, which can harm their health and increase the risk of other medical problems. Some people in this study may also have type 2 diabetes, a condition in which the body does not use insulin properly, causing blood sugar levels to become too high. This study is seeking participants in Japan who: * Have obesity disease. * May have type 2 diabetes. * Meet the study-specific age, weight and health requirements. About 180 adults will take part in this study. Participants will be randomly assigned to receive either berobenatide or a placebo. A placebo looks like the study medicine but does not contain any active medicine. Berobenatide or placebo will be given as an injection under the skin of the abdomen (belly area). The study will compare the experiences of people receiving berobenatide with those receiving placebo to determine whether berobenatide can help people lose weight. The study will also assess the safety of berobenatide and its effects on body weight and other health measures. People will take part in this study for about 22 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.